Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Enterprise Value (2020 - 2026)

Cytek Biosciences filings provide 6 years of Enterprise Value readings, the most recent being -$90.9 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 7.99% to -$90.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$90.9 million, a 7.99% increase, with the full-year FY2025 number at -$90.9 million, up 7.99% from a year prior.
  • Enterprise Value hit -$90.9 million in Q4 2025 for Cytek Biosciences, up from -$93.3 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$75.5 million in Q2 2025 to a low of -$364.6 million in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$163.6 million (2023), compared with a mean of -$197.7 million.
  • Biggest five-year swings in Enterprise Value: crashed 132.67% in 2022 and later skyrocketed 62.42% in 2023.
  • Cytek Biosciences' Enterprise Value stood at -$364.6 million in 2021, then rose by 17.86% to -$299.5 million in 2022, then soared by 44.03% to -$167.6 million in 2023, then surged by 41.09% to -$98.7 million in 2024, then rose by 7.99% to -$90.9 million in 2025.
  • The last three reported values for Enterprise Value were -$90.9 million (Q4 2025), -$93.3 million (Q3 2025), and -$75.5 million (Q2 2025) per Business Quant data.